NORTH CHICAGO, Ill., Nov. 30, 2015 /PRNewswire/ -- AbbVie, is introducing Good Morning Hypothyroidism (GMH), an all-inclusive program that focuses on a daily routine for managing the life-long condition of hypothyroidism. When and how patients take their medication can affect the way the body absorbs it so resources encouraging patients to establish and follow to their a daily routine are important. The goal of the new website www.OurMorningRoutine.com is to help patients better manage their hypothyroidism by establishing a daily routine, spirit of connection, and a sense of community through tools and resources such as a patient journal, medication refill reminder and a network of hypothyroidism patients.
This patient network called the Before Breakfast Club Ambassadors shares stories of individual diagnosis, routines and how they manage their hypothyroidism every day. Patients describe the importance of taking their medication at the same time before breakfast every morning as prescribed by their healthcare professional.[ii] As the new face of Synthroid.com, the website provides educational resources about the condition as well as SYNTHROID® (levothyroxine sodium tablets, USP) product information, coupons and saving card offers.
"Effectively managing hypothyroidism begins with understanding the disease," said Michael Robinson M.D., vice president of AbbVie U.S. Medical Affairs. "Good Morning Hypothyroidism takes patient education to the next level by providing inspiration to not only learn, but remain motivated in the management of this life-long condition."
Hypothyroidism affects millions of people in the U.S. and as many as ten percent of women may have some degree of thyroid hormone deficiency.[i] The thyroid gland is a butterfly-shaped endocrine gland located in the lower front of the neck, which produces thyroid hormones that help regulate certain functions of the body. Hypothyroidism, an underactive thyroid gland, is a common condition in which the thyroid gland cannot produce enough thyroid hormone to keep the body functioning properly.[iii]
Visit Synthroid.com to learn more.[ii]
About Synthroid
SYNTHROID® (levothyroxine sodium tablets, USP) is a prescription, man-made thyroid hormone that is used to treat a condition called hypothyroidism, except in cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid gland (thyroiditis). It is meant to replace a hormone that is usually made by your thyroid gland. Generally, thyroid replacement treatment is to be taken for life.
IMPORTANT SAFETY INFORMATION
This is the most important safety information you should know about SYNTHROID. For more information, talk with your doctor.
Please click to see full Prescribing Information including Black Box Warning or visit: www.rxabbvie.com/pdf/synthroid.pdf
Synthroid is a prescription medication. For more information, visit www.synthroid.com
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).
If you cannot afford your medication, contact http://www.pparx.org for assistance.
About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in AbbVie's 2014 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
[i] Norman, James. "About Hypothyroidism." EndocrineWeb.com. http://www.endocrineweb.com/conditions/thyroid/hypothyroidism-too-little-thyroid-hormone. Accessed February 23, 2015.
[ii] SYNTHROID [package insert].
[iii] American Thyroid Association. Hypothyroidism: A Booklet for Patients and Their Families. 2013; 4.
Photo - http://photos.prnewswire.com/prnh/20151124/290696
SOURCE AbbVie
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?